A letter about FDA oncology consolidation reopens debate among cancer groups; FDA asks groups not to send letters, invites discussion.
Also in this 12-page issue: GM Cancer Research Foundation awards annual prizes to four scientists.
Age-adjusted cancer incidence and mortality down slightly, annual report finds.
Bills in House, Senate, would give FDA authority over tobacco products.
Surgeon General’s report adds to list of smoking-related cancers, other diseases.
ASCO honors physicians for clinical trials participation.
President’s Cancer Panel urges comprehensive health care reform, provision of services for cancer survivors.
Funding opportunities listed.
Trending Stories
- Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Letai: MCEDs are a “great ideal”—alas, the data don’t support widespread use
“Projecting sub-ideal tests across a large population can cause harm,” Letai says, as Galleri cruises toward FDA approval - As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Oncology has a semantics problem: How do we define “early stage”?
